Order Article Reprints

Godwin CD, Rodríguez-Arbolí E, Othus M, Halpern AB, Appelbaum JS, Percival M-EM, Hendrie PC, Oehler VG, Keel SB, Abkowitz JL, et al. Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms. Cancers. 2022; 14(12):2934. https://doi.org/10.3390/cancers14122934

Godwin, Colin D., Eduardo Rodríguez-Arbolí, Megan Othus, Anna B. Halpern, Jacob S. Appelbaum, Mary-Elizabeth M. Percival, Paul C. Hendrie, Vivian G. Oehler, Siobán B. Keel, Janis L. Abkowitz, and et al. 2022. "Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms" Cancers 14, no. 12: 2934. https://doi.org/10.3390/cancers14122934

Godwin, C. D., Rodríguez-Arbolí, E., Othus, M., Halpern, A. B., Appelbaum, J. S., Percival, M.-E. M., Hendrie, P. C., Oehler, V. G., Keel, S. B., Abkowitz, J. L., Cooper, J. P., Cassaday, R. D., Estey, E. H., & Walter, R. B. (2022). Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms. Cancers, 14(12), 2934. https://doi.org/10.3390/cancers14122934